This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stein, C. A. Articles by Cohen, J. S. Search for Related Content PubMed PubMed Citation Articles by Stein, C. A. Articles by Cohen, J. S.

Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review

Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892

The past several years have seen an explosive growth in the application of antisense oligodeoxynucleotides as modulators of gene expression. In this review, we discuss the various classes of compounds currently receiving attention. These include unmodified oligodeoxynucleotides, methylphosphonates, phosphorothioates, and -oligonucleotides. The relative advantages and disadvantages of each class with regard to parameters such as (a) duplex stability (b) nuclease resistance, and (c) effectiveness of specific gene inhibition are noted. Oligodeoxynucleotides covalently linked to intercalating and other reactive groups are also described, as are possible mechanisms of oligodeoxynucleotide action. Finally, we consider potential future directions for this field and note that it holds the promise for specific gene therapy.

Received 6/17/87. Revised 10/30/87. Revised 1/26/88. Accepted 2/19/88.

This article has been cited by other articles:

				C. Torres-Farfan, L. Abarzua-Catalan, F. J. Valenzuela, N. Mendez, H. G. Richter, G. J. Valenzuela, and M. Seron-Ferre Cryptochrome 2 Expression Level Is Critical for Adrenocorticotropin Stimulation of Cortisol Production in the Capuchin Monkey Adrenal Endocrinology, June 1, 2009; 150(6): 2717 - 2722. [Abstract] [Full Text] [PDF]

				D. B. Fenske, A. Chonn, and P. R. Cullis Liposomal Nanomedicines: An Emerging Field Toxicol Pathol, January 1, 2008; 36(1): 21 - 29. [Abstract] [Full Text] [PDF]

				J Riedemann and V M Macaulay IGF1R signalling and its inhibition Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S33 - S43. [Abstract] [Full Text] [PDF]

				J. Flynn, R. W. Berg, T. Wong, M. van Aken, M. D. Vincent, M. Fukushima, and J. Koropatnick Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol. Cancer Ther., June 1, 2006; 5(6): 1423 - 1433. [Abstract] [Full Text] [PDF]

				P. M. Reuben, Y. Sun, and H. S. Cheung Basic Calcium Phosphate Crystals Activate p44/42 MAPK Signal Transduction Pathway via Protein Kinase C{micro} in Human Fibroblasts J. Biol. Chem., August 20, 2004; 279(34): 35719 - 35725. [Abstract] [Full Text] [PDF]

				R. Oulton and L. Harrington A Human Telomerase-associated Nuclease Mol. Biol. Cell, July 1, 2004; 15(7): 3244 - 3256. [Abstract] [Full Text] [PDF]

				K. Hemmrich, C. V. Suschek, G. Lerzynski, O. Schnorr, and V. Kolb-Bachofen Specific iNOS-targeted antisense knockdown in endothelial cells Am J Physiol Cell Physiol, August 1, 2003; 285(2): C489 - C498. [Abstract] [Full Text] [PDF]

				M. M. Thakkar, S. Winston, and R. W. McCarley A1 Receptor and Adenosinergic Homeostatic Regulation of Sleep-Wakefulness: Effects of Antisense to the A1 Receptor in the Cholinergic Basal Forebrain J. Neurosci., May 15, 2003; 23(10): 4278 - 4287. [Abstract] [Full Text] [PDF]

				P. Karayiannis Hepatitis B virus: old, new and future approaches to antiviral treatment J. Antimicrob. Chemother., April 1, 2003; 51(4): 761 - 785. [Abstract] [Full Text] [PDF]

				M. B. Sewer and M. R. Waterman cAMP-dependent Protein Kinase Enhances CYP17 Transcription via MKP-1 Activation in H295R Human Adrenocortical Cells J. Biol. Chem., February 28, 2003; 278(10): 8106 - 8111. [Abstract] [Full Text] [PDF]

				S. Ohno, M. Yoshimoto, S. Honda, S. Miyachi, T. Ishida, F. Itoh, T. Endo, S. Chiba, and K. Imai The Antisense Approach in Amyloid Light Chain Amyloidosis: Identification of Monoclonal Ig and Inhibition of Its Production by Antisense Oligonucleotides in In Vitro and In Vivo Models J. Immunol., October 1, 2002; 169(7): 4039 - 4045. [Abstract] [Full Text] [PDF]

				S. R. Inamdar, K. M. Eyster, and E. H. Schlenker Genome and Hormones: Gender Differences in Physiology: Selected Contribution: Estrogen receptor-{alpha} antisense decreases brain estrogen receptor levels and affects ventilation in male and female rats J Appl Physiol, October 1, 2001; 91(4): 1886 - 1892. [Abstract] [Full Text] [PDF]

				F. Shi, A. Nomden, V. Oberle, Jan. B. F. N. Engberts, and D. Hoekstra Efficient cationic lipid-mediated delivery of antisense oligonucleotides into eukaryotic cells: down-regulation of the corticotropin-releasing factor receptor Nucleic Acids Res., May 15, 2001; 29(10): 2079 - 2087. [Abstract] [Full Text] [PDF]

				Z. Lei, L. Zhang, L. R. Zhang, J. Chen, J. M. Min, and L. H. Zhang Hybrid characteristics of oligonucleotides consisting of isonucleoside 2',5'-anhydro-3'-deoxy-3'-(thymin-1-yl)-D-mannitol with different linkage modes Nucleic Acids Res., April 1, 2001; 29(7): 1470 - 1475. [Abstract] [Full Text] [PDF]

				H J N Andreyev, P J Ross, D Cunningham, and P A Clarke Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma Gut, February 1, 2001; 48(2): 230 - 237. [Abstract] [Full Text] [PDF]

				R. Morishita, G. H. Gibbons, N. Tomita, L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau Antisense Oligodeoxynucleotide Inhibition of Vascular Angiotensin-Converting Enzyme Expression Attenuates Neointimal Formation : Evidence for Tissue Angiotensin-Converting Enzyme Function Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 915 - 922. [Abstract] [Full Text] [PDF]

				R. Morishita, J. Higaki, N. Tomita, and T. Ogihara Application of Transcription Factor "Decoy" Strategy as Means of Gene Therapy and Study of Gene Expression in Cardiovascular Disease Circ. Res., June 1, 1998; 82(10): 1023 - 1028. [Abstract] [Full Text] [PDF]

				A. D. Taylor, H. C. Christian, J. F. Morris, R. J. Flower, and J. C. Buckingham An Antisense Oligodeoxynucleotide to Lipocortin 1 Reverses the Inhibitory Actions of Dexamethasone on the Release of Adrenocorticotropin from Rat Pituitary Tissue in Vitro Endocrinology, July 1, 1997; 138(7): 2909 - 2918. [Abstract] [Full Text] [PDF]

				N. Meiri, C. Ghelardini, G. Tesco, N. Galeotti, D. Dahl, D. Tomsic, S. Cavallaro, A. Quattrone, S. Capaccioli, A. Bartolini, et al. Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat PNAS, April 29, 1997; 94(9): 4430 - 4434. [Abstract] [Full Text] [PDF]

				F. I. Raynaud, R. M. Orr, P. M. Goddard, H. A. Lacey, H. Lancashire, I. R. Judson, T. Beck, B. Bryan, and F. E. Cotter Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 420 - 427. [Abstract] [Full Text]

				C. Pichon, K. Arar, A. J. Stewart, M. D. Dodon, L. Gazzolo, P. J. Courtoy, R. Mayer, M. Monsigny, and A.-C. Roche Intracellular Routing and Inhibitory Activity of Oligonucleopeptides Containing a KDEL Motif Mol. Pharmacol., March 1, 1997; 51(3): 431 - 438. [Abstract] [Full Text] [PDF]

				R. Morishita, G. H. Gibbons, M. Horiuchi, M. Nakajima, K. E. Ellison, W. Lee, Y. Kaneda, T. Ogihara, and V. J. Dzau Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(3): 213 - 222. [Abstract] [PDF]

				M. F. Taylor, J. D. Paulauskis, D. D. Weller, and L. Kobzik In Vitro Efficacy of Morpholino-modified Antisense Oligomers Directed against Tumor Necrosis Factor-alpha mRNA J. Biol. Chem., July 19, 1996; 271(29): 17445 - 17452. [Abstract] [Full Text] [PDF]

				J. G. Pickering, J. M. Isner, C. M. Ford, L. Weir, A. Lazarovits, E. F. Rocnik, and L. H. Chow Processing of Chimeric Antisense Oligonucleotides by Human Vascular Smooth Muscle Cells and Human Atherosclerotic Plaque : Implications for Antisense Therapy of Restenosis After Angioplasty Circulation, February 15, 1996; 93(4): 772 - 780. [Abstract] [Full Text]

				C. Stein and Y. Cheng Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science, August 20, 1993; 261(5124): 1004 - 1012. [Abstract] [PDF]

				W. Marshall and M. Caruthers Phosphorodithioate DNA as a potential therapeutic drug Science, March 12, 1993; 259(5101): 1564 - 1570. [Abstract] [PDF]

				T Diekwisch, S David, P Bringas, V Santos, and H. Slavkin Antisense inhibition of AMEL translation demonstrates supramolecular controls for enamel HAP crystal growth during embryonic mouse molar development Development, January 2, 1993; 117(2): 471 - 482. [Abstract] [PDF]

				D A Rappolee, K S Sturm, O Behrendtsen, G A Schultz, R A Pedersen, and Z Werb Insulin-like growth factor II acts through an endogenous growth pathway regulated by imprinting in early mouse embryos. Genes & Dev., June 1, 1992; 6(6): 939 - 952. [Abstract] [PDF]

				M. K. Sachs Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than With Azidothymidine Arch Intern Med, March 1, 1992; 152(3): 485 - 501. [Abstract] [PDF]

				J. Buchanan, H. B. Lee, and R. D. Lauper Recombinant DNA Technology Journal of Pharmacy Practice, January 1, 1991; 4(2): 87 - 93. [PDF]

				B. F. Trump Molecular Mechanisms of Genetic Deregulation in Toxicity and Carcinogenesis July 20-25, 1991, The Gant Conference Center, Aspen, Colorado: Program and Abstracts Toxicol Pathol, January 1, 1991; 19(4-2): 625 - 669. [PDF]

				S. Bechoua and L. W. Daniel Phospholipase D Is Required in the Signaling Pathway Leading to p38 MAPK Activation in Neutrophil-like HL-60 Cells, Stimulated by N-Formyl-methionyl-leucyl-phenylalanine J. Biol. Chem., August 17, 2001; 276(34): 31752 - 31759. [Abstract] [Full Text] [PDF]